Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Recursion Pharmaceuticals, Inc. - Class A Common Stock
(NQ:
RXRX
)
2.450
-0.270 (-9.93%)
Official Closing Price
Updated: 4:15 PM EST, Nov 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Recursion Pharmaceuticals, Inc. - Class A Common Stock
< Previous
1
2
3
4
5
Next >
How AI and Anticancer Peptides Could Reshape the Future of Cancer Treatment
November 18, 2026
EQNX::TICKER_START (NASDAQ:MEDS),(NASDAQ:NEO),(NASDAQ:ANT),(NASDAQ:RXRX),(NASDAQ:OBIO) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
How AI and Anticancer Peptides Could Reshape the Future of Cancer Treatment
November 18, 2026
Advanced AI Platforms Are Helping Researchers Identify New Cancer Targets, Engineer Promising Peptides, and Accelerate Next-Generation Drug Development
From
FN Media
Via
GlobeNewswire
Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis
November 18, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Participate in Upcoming Investor Conferences
November 11, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair
November 02, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
New Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP, with Activity Across the GI Tract and in Larger, Higher-Risk Polyps
November 02, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Appoints Fred Hassan as Chair of the Board
November 02, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Next-Gen Biotech: RXRX, OCGN, SNTI, VIVS, ONCO Stocks to Watch
October 28, 2026
Via
AB Newswire
Topics
Artificial Intelligence
Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3
October 26, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
October 15, 2026
Potential first-in-class dual targeting inhibitor oral small molecule to enter Sanofi’s development pipeline, with phase 1 clinical study currently planned to begin in 2027
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock
October 15, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone
October 15, 2026
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
The Market Just Told You Which Layer Of AI Biology It Is Paying For
September 03, 2026
Issued on behalf of MindWalk Holdings Corp.
From
Market Updates
Via
GlobeNewswire
Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
August 05, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Participate in Upcoming Investor Conferences
August 04, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
July 31, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th
July 29, 2026
Company to host public Earnings call on August 5th at 8:00 am ET / 6:00 am MT / 1:00 pm BST
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Participate in Upcoming Investor Conferences
June 02, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
May 29, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
TechMediaBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Advances AI Voice-Based Intoxication Detection as Real-Time Diagnostics Market Expands
May 11, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
The Future of Intoxication Detection May Be in Your Voice
May 11, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
The Future of Intoxication Detection May Be in Your Voice
May 11, 2026
From
BioMedWire
Via
GlobeNewswire
Recursion Reports First Quarter Financial Results and Provides Business Update
May 06, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Announces Board Transition
April 30, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6
April 29, 2026
Company to host public Earnings Call on May 6 at 8:00 am ET / 6:00 am MT / 1:00 pm BST
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Participate in Upcoming Investor Conferences
April 07, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform
March 31, 2026
From
Citeline
Via
GlobeNewswire
Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer
March 25, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Stocks Under $5 to Watch Now: LRMR, RXRX, NDRA, BTQ, CDIO Watch Now!
February 26, 2026
Via
AB Newswire
Topics
Artificial Intelligence
Intellectual Property
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 25, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit